Here's how a big pharma company shops for its future: sometimes it's about buying the smartest data, and sometimes it's about picking up a promising new molecule. Gilead Sciences Inc. (GILD) is doing both at once, announcing an expanded partnership with Tempus AI Inc. (TEM) and a new licensing deal with Kymera Therapeutics Inc. (KYMR) to bulk up its cancer-fighting capabilities.

Think of it as a two-pronged strategy. On one side, you've got the information engine. Gilead is broadening its multi-year collaboration with Tempus, a company that deals in the currency of modern medicine: massive, de-identified datasets. Gilead has already been using Tempus's data trove for things like designing clinical trials and figuring out which biomarkers to target. The expanded deal gives Gilead enterprise-wide access to Tempus's AI-powered Lens platform, which is expected to deliver even broader datasets across multiple cancer types, along with dedicated analytical services from Tempus.

It's a sign of the times in drug development. The old model of throwing compounds at a disease and seeing what sticks is getting a high-tech makeover. Now, the idea is to use artificial intelligence to sift through real-world evidence—how patients actually respond in various settings—to make smarter, faster decisions about which drugs to develop and for whom. This isn't just about efficiency; it's the bedrock of precision medicine, where treatments are tailored to the genetic and molecular profile of a patient's cancer.

On the other side of the strategy is the actual drug candidate. Separately, Gilead has exercised its option to exclusively license a molecule called KT-200 from Kymera. This triggers a $45 million milestone payment to Kymera. So, what is KT-200? It's described as a first-in-class, oral CDK2 molecular glue degrader. In simpler terms, it's a new type of pill designed to break down a specific protein (CDK2) that cancer cells rely on to grow and divide.

The early science looks promising. In preclinical studies, KT-200 showed it could degrade the CDK2 protein at very low concentrations. It was active in cancer cell lines and tumor models with a specific genetic alteration (CCNE1 amplification), showed potential to cross into the brain—a crucial hurdle for treating brain cancers—and had a favorable safety profile so far. Gilead's plan is to now shepherd KT-200 into the studies needed to file an investigational new drug (IND) application, which they're targeting for 2027.

The financial setup with Kymera is a classic biotech partnership structure. Kymera could receive up to $750 million in total payments from Gilead, including various development and commercial milestones. The company has already secured $85 million from upfront and option-related payments. On top of that, Kymera is eligible for tiered royalties on future net sales, ranging from high single-digit to mid-teens percentages. Gilead gets the global rights to develop, manufacture, and sell any products that come out of this partnership.

This isn't a brand-new relationship. Gilead and Kymera initially teamed up back in June 2025 to work on a molecular glue degrader program targeting CDK2. The exercise of this option on KT-200 is the next logical step in that collaboration.

As for how the market reacted on Thursday, it was a mixed bag. Gilead shares were up 0.26% at $141.91, Kymera stock was up 0.94% at $88.02, and Tempus stock was down 3.87% at $45.64 at the time of publication, according to market data.